Pacific Biosciences of California(US:PACB) ZACKSยท2025-01-08 00:36Company Performance - Pacific Biosciences of California (PACB) closed at $2, reflecting a +0.5% change from the previous day, outperforming the S&P 500's daily loss of 1.11% [1] - Over the past month, PACB shares have decreased by 8.72%, which is worse than the Medical sector's loss of 6.22% and the S&P 500's loss of 1.7% [1] Earnings Forecast - The upcoming earnings report for Pacific Biosciences is expected to show an EPS of -$0.20, representing a 25.93% increase from the same quarter last year [2] - Revenue is anticipated to be $40.9 million, indicating a 29.92% decrease compared to the same quarter last year [2] Analyst Estimates - Recent adjustments to analyst estimates for Pacific Biosciences are being closely monitored, as they often reflect changes in near-term business trends [3] - Positive changes in estimates suggest analyst optimism regarding the company's business and profitability [3] Zacks Rank and Industry Performance - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), indicates that stocks rated 1 have delivered an average annual return of +25% since 1988 [5] - Currently, Pacific Biosciences holds a Zacks Rank of 3 (Hold), with the consensus EPS projection having decreased by 4.95% in the past 30 days [5] - The Medical - Instruments industry, part of the Medical sector, has a Zacks Industry Rank of 69, placing it in the top 28% of over 250 industries [6]